Latest research on Zytiga

Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.

Latest findings

Thus ONC1-13B should be better suited for co-treatment therapy with other drugs, including CYP3A substrates, for example with Zytiga. [source, 2014]
Recently several new drugs have been approved for the treatment of CRPC: Jevtana (cell division inhibitor), Zytiga (CYP17A inhibitor, androgene blockator) and XTANDI (androgen receptor antagonist). [source, 2014]
Two of them - Zytiga and XTANDI, are targeting androgen-dependant axis, thus providing evidence of significant importance of this pathway as a target for treatment. [source, 2014]
Zytiga (abiraterone), Jevtana (cabazitaxel), Xtandi (enzalutamide), Xofigo (radium Ra 223 dichloride), and Provenge (sipuleucel-T) were recently approved (2010–2013) by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of mCRPC. [source, 2014]
Recently two new hormonal therapy agents have been approved by the US Food and Drug Administration (FDA) for the treatment of patients with mCRPC: Abiraterone acetate (Zytiga) [26] and enzalutamide previously known as MDV3100 (now called Xtandi) [27]. [source, 2014]
Abiraterone (Zytiga) is an oral, selective and potent irreversible inhibitor of CYP17A, which is an enzyme that catalyzes both 17 alpha-hydroxylase and 17, 20-lyase reactions. [source, 2014]
One published report of abiraterone (Zytiga) and Prednisone included men with NM-CRPC [43]. [source, 2014]
These findings were later validated in the randomized phase III study that led to the approval of the CYP-17 inhibitor abiraterone (Zytiga, Janssen Biotech) [35]. [source, 2014]
To determine the effect of NRs on PCa cell growth, androgen-sensitive (LNCaP) and -insensitive (PC-3, C4-2B) and castration-resistant (22Rv1) human prostate cancer cells were treated with NRs (VN/66-1, VNLG-145, -146, -147, -148, -152, -153), VN/14-1, ATRA, 4-HPR, Casodex, Abiraterone acetate (AA) (Zytiga) and MDV3100 (Enzalutamide) (Figure 1) and assessed for cell viability by MTT assay. [source, 2014]
In addition, Zytiga (abiraterone acetate), the CYP17 inhibitor that is able to form non-reversible products to lower its activity by reducing the biosynthesis of androgenic hormone, was initially discovered by British Cancer Institute. [source, 2014]